Asthma

AHF Backs FTC Challenge to Big Pharma Junk Patents

Retrieved on: 
Friday, May 3, 2024
Advocacy Group Opinion, Public Policy, Government, Healthcare Reform, AIDS, White House, Federal Government, Health, Pharmaceutical, General Health, Other Policy Issues, Public, FTC, United, Weight loss, Patent, GSK, AIDS Healthcare Foundation, HIV, AHF, Asthma, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) voiced support for the U.S. Federal Trade Commission (FTC) taking action this week to challenge several major pharmaceutical companies, including GSK, for anticompetitive use of so-called junk patents that prevent generic competition and keep drug prices artificially high.

Key Points: 
  • AIDS Healthcare Foundation (AHF) voiced support for the U.S. Federal Trade Commission (FTC) taking action this week to challenge several major pharmaceutical companies, including GSK, for anticompetitive use of so-called junk patents that prevent generic competition and keep drug prices artificially high.
  • “Big pharma is abusing the patent system by filing multiple derivative patents on existing drugs – which is not innovation – it’s greed.
  • AHF has worked closely with civil society partners to address these abuses.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240503187473/en/

Allergy and Asthma Experts Prepare for Air Quality Awareness Week

Retrieved on: 
Friday, May 3, 2024
AAAAI, American Academy, Public, Climate change, Allergy, Multimedia, Pollen, Asthma, Immunology, Air pollution, Cochineal

MILWAUKEE, May 3, 2024 /PRNewswire-PRWeb/ -- May 6 - 10 is Air Quality Awareness Week, and experts in the allergy/immunology field are addressing the impact of air quality on public health.

Key Points: 
  • MILWAUKEE, May 3, 2024 /PRNewswire-PRWeb/ -- May 6 - 10 is Air Quality Awareness Week, and experts in the allergy/immunology field are addressing the impact of air quality on public health.
  • The effects of climate change, air pollution and other environmental factors can cause unique challenges for people living with asthma and allergies.
  • As leaders in the field of allergy, asthma and immunological disease, AAAAI experts are available to discuss the significant impact air quality has on those living with these challenges.
  • Candace Archie, The American Academy of Allergy, Asthma & Immunology, (414) 272-6071, [email protected] , aaaai.org
    View original content to download multimedia: https://www.prweb.com/releases/allergy-and-asthma-experts-prepare-for-ai...
    SOURCE The American Academy of Allergy, Asthma & Immunology

Breathing Joy Into Inhaler Use for Kids: Elijah-Alavi Foundation Launches HappyHalers

Retrieved on: 
Thursday, May 2, 2024
Education, Asthma, Collection, 3D, Friends, Child, Allergy, Global Initiative, Social stigma

NEW YORK, May 2, 2024 /PRNewswire/ -- Every year, over 500,000 kids in the US are rushed to the emergency room because of asthma. While rescue inhalers can prevent attacks from becoming life-threatening, many kids aren't using them like they should. Because kids with asthma often feel self-conscious or embarrassed to use their inhalers in public, they are ending up in the emergency room all too often. In fact, the Global Initiative for Asthma's 2023 main report revealed stigmatization as one of the top reasons people choose not to use their inhalers.

Key Points: 
  • In fact, the Global Initiative for Asthma's 2023 main report revealed stigmatization as one of the top reasons people choose not to use their inhalers.
  • The Elijah-Alavi Foundation joined forces with The Purpose Group to create HappyHalers—fun, 3D-printed inhaler covers designed to turn life-saving asthma treatment into something more enjoyable, engaging, and interactive.
  • "No child should ever feel embarrassed by their asthma," said Thomas Silvera, founder of the Elijah-Alavi Foundation.
  • HappyHalers are designed to go around a standard actuator, so they never change the function of an inhaler.

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Retrieved on: 
Thursday, May 2, 2024
TSX, Doctor of Philosophy, Esophagus, MPH, Immunoglobulin E, Allergic rhinitis, Asthma, Eosinophilic esophagitis, Pharmaceutical industry

VICTORIA, BC, May 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program.

Key Points: 
  • VICTORIA, BC, May 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced the formation of a Clinical Advisory Board for its gastrointestinal ("GI") program.
  • The Clinical Advisory Board is comprised of Dr. Evan Dellon (Chairman), Dr. Stephen Attwood, Dr. Albert Bredenoord, Dr. Donna Griebel, Dr. Ikuo Hirano and Dr. Roos Pouw.
  • The Clinical Advisory Board will work closely with Eupraxia as it continues its development of EP-104GI for eosinophilic esophagitis ("EoE"), which is currently in a Phase 1b/2a clinical trial.
  • "The formation of our Gastrointestinal Clinical Advisory Board comes at an exciting time for our Company, as we continue to generate clinical evidence in support of EP-104GI for the treatment of eosinophilic esophagitis," said Mark Kowalski, MD, PhD, Chief Medical Officer of Eupraxia.

Allergy & Asthma Day Capitol Hill on May 8: Advancing Health Equity for All

Retrieved on: 
Wednesday, May 1, 2024
Education, Congress, Law, Bangladesh Technical Education Board, Health equity, EPA, Investment, HELP, Risk, NIH, CDC, Allergy, Health, Collection, Research, Asthma, Native, Patient, Adrenaline, Legislation, Anaphylaxis, Clinical trial, Pharmaceutical industry

On May 8, Allergy & Asthma Network is hosting its 27th annual Allergy & Asthma Day Capitol Hill (AADCH) in Washington, DC to advocate for healthcare policies and legislation that leave no one behind – regardless of race, ethnicity, education, income level or where they live.

Key Points: 
  • On May 8, Allergy & Asthma Network is hosting its 27th annual Allergy & Asthma Day Capitol Hill (AADCH) in Washington, DC to advocate for healthcare policies and legislation that leave no one behind – regardless of race, ethnicity, education, income level or where they live.
  • The theme this year is "Breaking Barriers: Advancing Health Equity for All."
  • "Health disparities create barriers to accessing care and achieving optimal health," says Lynda Mitchell, CEO of Allergy & Asthma Network.
  • "We are excited to head back to Capitol Hill to advocate for legislation that is patient-first and reinforces health equity," says Charmayne Anderson, Director of Advocacy at Allergy & Asthma Network.

Knauf Announces New Performance+ Fiberglass Insulation Portfolio, CERTIFIED asthma & allergy friendly®

Retrieved on: 
Wednesday, May 1, 2024
Education, EPA, Risk, Certification, Knauf, Marketing, Volatile organic compound, Innovation, Asthma, ASL, AAFA, Allergy, Formaldehyde, Atmosphere, HVAC

SHELBYVILLE, Ind., May 1, 2024 /PRNewswire/ -- Knauf Insulation, Inc., a leading, family-owned global manufacturer of fiberglass insulation, today announced the launch of its new HVAC fiberglass insulation product line, Knauf Performance+. This product line is the first of its kind to be CERTIFIED asthma & allergy friendly® and the only HVAC fiberglass insulation line that is formaldehyde-free.

Key Points: 
  • SHELBYVILLE, Ind., May 1, 2024 /PRNewswire/ -- Knauf Insulation, Inc., a leading, family-owned global manufacturer of fiberglass insulation, today announced the launch of its new HVAC fiberglass insulation product line, Knauf Performance+.
  • This product line is the first of its kind to be CERTIFIED asthma & allergy friendly® and the only HVAC fiberglass insulation line that is formaldehyde-free.
  • The asthma & allergy friendly® Certification Program established by the Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL), certifies products more suitable for people with asthma and allergies.
  • The Knauf Performance+ line is formaldehyde-free and boasts low VOCs (Volatile Organic Compounds) levels, which significantly reduces the risk of asthma and allergy triggers.

Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020

Retrieved on: 
Tuesday, April 30, 2024
Foresight, Clinical trial, Trial of the century, Asthma, Safety, Pharmacokinetics, COPD, Pharmaceutical industry

TAIPEI, April 30, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia.

Key Points: 
  • TAIPEI, April 30, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia.
  • The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled, single-center, single, and multiple ascending oral dose study to evaluate the safety, tolerability, and pharmacokinetics of FP-020 in healthy volunteers.
  • "The initiation of this Phase 1 trial underscores our commitment to advancing innovative therapies to benefit patients with severe asthma and COPD.
  • Additionally, we are working diligently to build a broad franchise leveraging our multiple MMP-12 inhibitors across several therapeutic areas."

Foresee Pharmaceuticals Announces Poster Presentation and Participation at the 2024 American Thoracic Society International Conference

Retrieved on: 
Monday, April 29, 2024
Efficacy, Safety, Foresight, ATS, Pulmonary hypertension, Conference, House, ALDH2, Human, SNP, SVP, Aldehyde, HDM, Lung, American Thoracic Society, Asthma, Pharmacology, Pharmaceutical industry

TAIPEI, April 29, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today that it will actively participate in and present two posters at the 2024 American Thoracic Society (ATS) International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024.

Key Points: 
  • TAIPEI, April 29, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today that it will actively participate in and present two posters at the 2024 American Thoracic Society (ATS) International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024.
  • "The WINDWARD Phase 2 study is designed to evaluate the safety, tolerability, and efficacy of FP-045 in patients with PH-ILD.
  • We could not be more confident with the role and importance of MMP-12 in immune-fibrotic diseases, particularly in the lung.
  • The posters will become available on the Foresee website after the conference.

Hospitalist Co-Management Program for Neurosurgery Inpatients Reduces Medical Complications and Length of Stay

Retrieved on: 
Thursday, May 2, 2024
Mortality, Patient, Hospital, Length of stay, Diabetes, Neurosurgery, Length, Quality, Patient safety, Incidence, Editorial, Hospital medicine, Medicine, MBA, Asthma, Chronic kidney disease, Heart failure, Pharmaceutical industry

A new study in the May 2024 issue of The Joint Commission Journal on Quality and Patient Safety (JQPS) evaluated the impact of a hospitalist co-management program on clinical outcomes in neurosurgical patients.

Key Points: 
  • A new study in the May 2024 issue of The Joint Commission Journal on Quality and Patient Safety (JQPS) evaluated the impact of a hospitalist co-management program on clinical outcomes in neurosurgical patients.
  • The study, “Impact of a Hospitalist Co-Management Program on Medical Complications and Length of Stay in Neurosurgical Patients,” aimed to determine whether general neurosurgery inpatients benefit from a hospitalist-led co-management program in terms of mortality, complications and use of resources.
  • During the intervention period, patients admitted to a neurosurgery inpatient unit were included in the co-management program if they were:
    Older than 65 years old.
  • Findings showed significant reduction in the incidence of relevant medical complications and length of stay in the co-managed patients but revealed no difference in in-hospital mortality.

Maryland Becomes Fourth State to Enact Elijah’s Law to Protect Kids with Food Allergies

Retrieved on: 
Friday, April 26, 2024
Child care, Policy, Territory, Allergy, Asthma, Senate, AAFA, Food, Legislation, Interstate 95 in Maryland, Anaphylaxis, Memory, EAF, Nursing

Wes Moore, enacts policies designed to protect children with food allergies in child care centers.

Key Points: 
  • Wes Moore, enacts policies designed to protect children with food allergies in child care centers.
  • “We commend the state legislature for passing Elijah’s Law and taking steps to ensure uniform practices relative to food allergies in child care centers in Maryland,” said Kenneth Mendez, President and CEO of AAFA.
  • The bill ensures child care centers take steps to manage food allergies for the children in their care.
  • Maryland is the fourth state in the nation to pass Elijah’s Law, following New York, Illinois, and Virginia.